About CytRx (NASDAQ:CYTR)
CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company's product candidate is the aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It also has completed Phase IIb and Phase Ib/II clinical trials with aldoxorubicin as a first-line therapy for STS; a Phase Ib clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors. The company is also developing anti-cancer drug conjugates, which utilizes its Linker Activated Drug Release technology. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYTR
CUSIPN/A
Phone310-826-5648
Debt
Debt-to-Equity RatioN/A
Current Ratio1.56%
Quick Ratio1.56%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$100,000.00
Price / Sales473.88
Cash FlowN/A
Price / CashN/A
Book Value$0.66 per share
Price / Book2.56
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-34,980,000.00
Net MarginsN/A
Return on Equity-187.35%
Return on Assets-65.74%
Miscellaneous
Employees20
Outstanding Shares28,040,000
CytRx (NASDAQ:CYTR) Frequently Asked Questions
What is CytRx's stock symbol?
CytRx trades on the NASDAQ under the ticker symbol "CYTR."
When did CytRx's stock split? How did CytRx's stock split work?
CytRx shares reverse split before market open on Wednesday, November 1st 2017. The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 31st 2017. An investor that had 100 shares of CytRx stock prior to the reverse split would have 17 shares after the split.
How were CytRx's earnings last quarter?
CytRx (NASDAQ:CYTR) announced its quarterly earnings results on Monday, March, 19th. The biotechnology company reported ($0.16) earnings per share for the quarter. The biotechnology company earned $0.10 million during the quarter. View CytRx's Earnings History.
When is CytRx's next earnings date?
What price target have analysts set for CYTR?
1 Wall Street analysts have issued 1 year price objectives for CytRx's shares. Their forecasts range from $24.00 to $24.00. On average, they anticipate CytRx's stock price to reach $24.00 in the next twelve months. View Analyst Ratings for CytRx.
Who are some of CytRx's key competitors?
Some companies that are related to CytRx include Curis (CRIS), Aevi Genomic Medicine (GNMX), Applied Genetic Technologies (AGTC), Cidara Therapeutics (CDTX), aTyr Pharma (LIFE), Genocea Biosciences (GNCA), Brainstorm Cell Therapeutics (BCLI), TRACON Pharmaceuticals (TCON), Proteon Therapeutics (PRTO), Vaxart (VXRT), Vical (VICL), Microbot Medical (MBOT), Neuralstem (CUR), Oncobiologics (ONS), TrovaGene (TROV), Windtree Therapeutics (WINT) and OXiGENE (MATN).
Who are CytRx's key executives?
CytRx's management team includes the folowing people:
- Mr. Steven A. Kriegsman, Chairman, Chief Exec. Officer and Pres (Age 76)
- Mr. John Y. Caloz, CFO, Chief Accounting Officer & Treasurer (Age 66)
- Dr. Bruce Spiegelman Ph.D., Member of Scientific Advisory Board of CytRx Laboratories Inc
- Dr. Luciano Rossetti M.D., Member of Scientific Advisory Board of CytRx Laboratories Inc
- Dr. Felix Kratz Ph.D., Sr. VP, Drug Devel. (Age 55)
Has CytRx been receiving favorable news coverage?
News coverage about CYTR stock has trended somewhat positive on Friday, Accern Sentiment reports. Accern scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. CytRx earned a coverage optimism score of 0.04 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 46.33 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of CytRx?
Shares of CYTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CytRx's stock price today?
One share of CYTR stock can currently be purchased for approximately $1.69.
How big of a company is CytRx?
CytRx has a market capitalization of $49.91 million and generates $100,000.00 in revenue each year. CytRx employs 20 workers across the globe.
How can I contact CytRx?
CytRx's mailing address is 11726 SAN VICENTE BOULEVARD SUITE 650, LOS ANGELES CA, 90049. The biotechnology company can be reached via phone at 310-826-5648 or via email at [email protected]
MarketBeat Community Rating for CytRx (CYTR)
MarketBeat's community ratings are surveys of what our community members think about CytRx and other stocks. Vote "Outperform" if you believe CYTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
CytRx (NASDAQ:CYTR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for CytRx in the last 12 months. Their average twelve-month price target is $24.00, suggesting that the stock has a possible upside of 1,320.12%. The high price target for CYTR is $24.00 and the low price target for CYTR is $24.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $24.00 | $24.00 | $24.00 | $21.00 |
| Price Target Upside: | 1,320.12% upside | 396.46% upside | 396.46% upside | 334.40% upside |
CytRx (NASDAQ:CYTR) Consensus Price Target History
CytRx (NASDAQ:CYTR) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
CytRx (NASDAQ:CYTR) Earnings History and Estimates Chart
CytRx (NASDAQ CYTR) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/8/2018 | | | | | | | N/A |  |
| 3/19/2018 | Q4 2017 | | ($0.16) | | $0.10 million | View | Listen | |
| 11/8/2017 | Q3 2017 | | ($0.33) | | | View | N/A | |
| 8/3/2017 | Q2 2017 | | ($0.42) | | | View | N/A | |
| 5/10/2017 | Q1 2017 | | ($0.60) | | | View | N/A | |
| 3/15/2017 | Q4 2016 | ($0.66) | ($0.60) | | $0.10 million | View | N/A | |
| 11/9/2016 | Q3 2016 | ($0.96) | ($0.78) | | | View | N/A | |
| 7/29/2016 | Q2 | ($1.14) | ($1.62) | | $0.10 million | View | N/A | |
| 5/11/2016 | Q116 | ($1.56) | ($1.14) | | | View | N/A | |
| 3/11/2016 | Q4 2015 | ($1.20) | ($2.10) | | $0.10 million | View | N/A | |
| 11/3/2015 | Q315 | ($1.44) | ($1.02) | | | View | N/A | |
| 8/3/2015 | Q215 | ($1.62) | ($1.50) | | | View | N/A | |
| 5/1/2015 | Q115 | ($1.26) | ($1.68) | | | View | N/A | |
| 3/10/2015 | Q4 2014 | ($1.62) | ($1.44) | | $0.10 million | View | N/A | |
| 11/4/2014 | Q314 | ($1.50) | ($0.60) | | | View | N/A | |
| 8/6/2014 | Q214 | ($1.20) | ($1.68) | | | View | N/A | |
| 5/1/2014 | Q1 2014 | | ($1.08) | | | View | N/A | |
| 3/5/2014 | | ($1.02) | ($1.50) | | $0.10 million | View | N/A | |
| 10/29/2013 | Q313 | ($1.32) | ($1.98) | $0.20 million | | View | N/A | |
| 8/6/2013 | Q2 2013 | ($1.14) | ($0.66) | | $0.20 million | View | N/A | |
| 5/9/2013 | Q113 | ($0.90) | ($1.38) | | | View | N/A | |
| 3/11/2013 | Q4 2012 | ($1.20) | ($1.26) | | | View | N/A | |
| 11/9/2012 | Q312 | | $0.42 | | | View | N/A | |
| 8/9/2012 | Q2 2012 | ($1.86) | ($1.34) | | | View | N/A | |
| 5/10/2012 | Q1 2012 | ($1.68) | ($1.76) | | | View | N/A | |
| 3/13/2012 | Q4 2011 | ($1.68) | ($1.72) | | | View | N/A | |
| 11/8/2011 | Q3 2011 | ($1.68) | ($1.05) | | | View | N/A | |
| 8/9/2011 | Q2 2011 | ($2.10) | ($1.43) | | | View | N/A | |
| 5/5/2011 | Q1 2011 | ($1.26) | ($2.60) | | | View | N/A | |
| 3/11/2011 | Q4 2010 | | $2.27 | | | View | N/A | |
| 11/8/2010 | Q3 2010 | ($2.10) | ($1.68) | | | View | N/A | |
| 8/9/2010 | Q2 2010 | ($2.10) | ($1.89) | | | View | N/A | |
| 5/6/2010 | Q1 2010 | ($1.68) | ($1.81) | | | View | N/A | |
| 3/15/2010 | Q4 2009 | ($1.68) | ($1.26) | | | View | N/A | |
| 11/9/2009 | Q3 2009 | $0.42 | $1.51 | | | View | N/A | |
| 8/10/2009 | Q2 2009 | ($1.68) | ($1.01) | | | View | N/A | |
| 5/12/2009 | Q1 2009 | ($1.68) | ($1.81) | | | View | N/A | |
| 3/13/2009 | Q4 2008 | ($1.68) | ($1.76) | | | View | N/A | |
| 11/7/2008 | Q3 2008 | ($1.68) | ($1.34) | | | View | N/A | |
| 8/12/2008 | Q2 2008 | ($2.52) | ($1.68) | | | View | N/A | |
| 5/20/2008 | Q1 2008 | ($3.36) | ($2.85) | | | View | N/A | |
| 4/2/2008 | Q4 2007 | | ($2.94) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
CytRx (NASDAQ:CYTR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
CytRx (NASDAQ CYTR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 6.13%
CytRx (NASDAQ CYTR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/3/2013 | Scott Bradford Patterson | major shareholder | Buy | 284,979 | $2.44 | $695,348.76 | 4,912,584 | |
| 11/7/2013 | Scott Bradford Patterson | Major Shareholder | Buy | 50,000 | $2.06 | $103,000.00 | | |
| 4/1/2013 | Scott Bradford Patterson | Major Shareholder | Buy | 4,083 | $2.70 | $11,024.10 | | |
| 3/20/2013 | Scott Bradford Patterson | Major Shareholder | Buy | 3,980 | $2.61 | $10,387.80 | | |
| 3/13/2013 | Scott Bradford Patterson | Major Shareholder | Buy | 55,360 | $2.67 | $147,811.20 | | |
| 10/22/2012 | Scott Bradford Patterson | Major Shareholder | Buy | 180,000 | $2.51 | $451,800.00 | | |
| 10/18/2012 | Scott Bradford Patterson | Major Shareholder | Buy | 1,200,000 | $2.50 | $3,000,000.00 | | |
(Data available from 1/1/2013 forward)
CytRx (NASDAQ CYTR) News Headlines
| Source: |
|
CytRx (NASDAQ:CYTR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
CytRx (NASDAQ:CYTR) Income Statement, Balance Sheet and Cash Flow Statement
CytRx (NASDAQ CYTR) Stock Chart for Friday, April, 20, 2018
Loading chart…
